Based on our results and these previous studies on the role of ENO1 in tumor progression and immune response, we propose that targeting ENO1/ENOA in cervical cancer will provide an additional therapeutic benefit and increase the patient survival. This evidence concerns the gene ENO1 and cervical carcinoma.